Tag Archives | healthcare reform

Risks Rising for Rally: Political Rhetoric Tempers Bulls

Risks Rising for Healthcare Sector As Harsh Political Rhetoric Returns Trump returns to drug pricing attacks. Healthcare sector lags. Opioid crisis blames drug distribution companies for easy access. Sector on hold awaiting Q3 earnings: XLV down 0.44% today near its 52 week high. The early rally in biotech and drug stocks reversed on the 10 […]

Continue Reading 0

Rayno BioBeat #4: Biotechs Weaken on Profit Taking…Update-2

Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and suggested last week […]

Continue Reading 0

Sector Rotation or Another Tech Wreck?

Tech Wreck Part 2? Or Just Profit Taking. Sector Rotation Away from Large Cap Growth (QQQ) to Value (XLF) Volatility Returns Tech and biotech stocks were hit from sector rotation with the NASDAQ down 2.18 % to and the QQQ down 2% to $136.75 as of mid-day trading. This is the second hit in June […]

Continue Reading 0

Biotech Stocks Sink with Broad Sell-Off on Political Realities…Updates

3/22 Update after close..Relief Rally Awaiting Tomorrow’s Vote Large Caps-mostly green with IBB up 0.54%. Mid Caps-some strength RDUS up 3.48% SGEN up 1.74 %, ,TSRO up 4.08%. Small caps XBI up 0.98%. NASDAQ up 0.48%. ========== Biotech Stocks Sink on Trump Comments Uncertainty Mounts for GOP Healthcare Plan-Fewer Patients Higher Costs? Worse Day of the Year […]

Continue Reading 0

More Drug Pricing Headwinds for Biotech Just as Tape Improves: Update-1 M&A Uptick

Update 2/8/17 12N EST Biotech Stocks Perk Up on M&A Rumors PARP Inhibitor stocks- Clovis Oncology (CLVS) up 3%, Tesaro (TSRO) up 12.5%. IBB and XBI flattish. EXEL up 2.7%. INCY up 1.78%. GWPH up 3.9%. Also Foundation Medicine (FMI) is up over 10% to $24 with no news. GILD down 9.7% to $66: maybe […]

Continue Reading 0

Rayno Biobeat #4: Sector Shift Underway but what’s next for biotech?…Update-1

Update-1 November 28 Another nasty day for biotech A bit of a selloff in the market indices today with the NASDAQ down 0.58% and the S&P down 0.53%. The highly touted Russell 2000 (IWM) was down 1.3% after a 15 day rally. But the real wreck was in biotech with the XBI down 3.09% and […]

Continue Reading 0

Biotech Investors Stung By Drug Pricing Flap…Update-1

Update-1… IBB Trying to hold the $280 line after media bashing of EpiPen Pricing- now they have a generic EpiPen for half the price! Biotech outflows are a concern (-$184M) Gilead Sciences (GILD) down 2.89% on new potential competition from GlaxoSmithK (GSK) HIV double therapy drug with cost savings. Choppy market in biotech with red screen […]

Continue Reading 0

BIO 2016: Imagine Was the Right Theme and Healthcare Disruption Is the Force

BIO International 2016 : “Imagine Who You will Meet” was an Appropriate Theme Healthcare Disruption Is Creating Reform BIO 2016 was an excellent meeting as usual because of the opportunity to hear thought leaders, policy makers, scientists and make connection with thousands of participants from around the world. Healthcare disruption, sustainability and patient access were […]

Continue Reading 0

Milken Institute Global Conference-Healthcare Reform I

Missed Opportunity in Health Reform-Wellness and Prevention On Monday April 26 a panel of executives  and leaders including Michael Milken, moderated by CNBC anchor Maria Bartiromo convened to discuss Health Reform in a session focused on “Prevention and Cures”. The primary focus of the discussion was the need for government policy and health reform to […]

Continue Reading 0

Healthcare Stocks up-Market absorbs Reform

Healthcare and biotech stocks were up today as expected following passage of the historic reform bill. Although there is a considerable amount of work to be done in enabling the historic legislation, uncertainty has been removed and the market can play it out. Many analysts and economists previously have forecasted upside potential for pharmaceutical, biotechnology […]

Continue Reading 0